Treatment of iron deficiency anemia with liposomal iron in inflammatory bowel disease: efficacy and impact on quality of life.

Background Anemia is a clinical condition frequently seen in patients with inflammatory bowel disease, which is responsible for a significant loss of quality of life. Objective To assess the efficacy and safety of using oral liposomal iron to treat iron deficiency anemia in inflammatory bowel disease patients, as well as assess the impact of this treatment on psychometric scores. Methods Patients with inactive/mildly active inflammatory bowel disease were screened for anemia in this interventional pilot study conducted from November 2016 to March 2018. Patients with mild anemia were treated with oral liposomal iron for 8 weeks. Main outcome measure The primary endpoint of the study was the response to liposomal oral iron therapy. Treatment response was defined as patients who achieved a hemoglobin increase of ≥ 1 g/dL and/or hemoglobin normalization by the 8th week of treatment. Results Out of 200 screened patients, 40 (20%) had anemia. Of the 21 patients who completed treatment, 13 (62%) responded to oral liposomal iron replacement therapy (mean increases of hemoglobin from 11.4 to 12.6 g/dL). The transferrin saturation index increased by an average of 10.2 (p = 0.006) and the quality of life by 26.3 (p < 0.0001). There was also a mean reduction of 9.2 in the perception of fatigue (p < 0.0001). Conclusion Treatment with oral liposomal iron is effective in improving mild iron deficiency anemia and quality of life, as well as in decreasing fatigue in patients with inactive or mildly active inflammatory bowel disease.

Expressão das metaloproteinases da matriz 2 e 9 na saliva de pacientes com doença obstrutiva crônica / Expression of matrix metalloproteinases -2 and -9 in saliva from patients with chronic obstructive pulmonary disease

O aumento da expressão das metaloproteinases da matriz extracelular (MPM) é considerado um importante fator no desenvolvimento da doença pulmonar obstrutiva crônica (DPOC). O presente estudo teve como objetivo avaliar os níveis de expressão da MPM-2 e MPM-9 na saliva de pacientes com DPOC em comparação com indivíduos saudáveis, verificando a viabilidade de usar a saliva para a caracterização de biomarcadores específicos em DPOC. Foram selecionados pacientes com DPOC (n=16) e controles saudáveis (n=9). Em ambos os grupos foram realizados teste espirométrico e obtidas amostras de saliva de cada indivíduo. Os níveis de MPM-2 e MPM-9 na saliva foram determinados pela técnica Westernblot. A MPM-2 e a MPM-9 foram significativamente maiores em pacientes com DPOC do que no grupo de indivíduos saudáveis. Foi encontrada moderada correlação negativa entre a concentração de MPM-2 e o volume expiratório forçado no primeiro segundo (r= -0,582, p=0,014) em pacientes com DPOC. Estes resultados abrem novas perspectivas para o estudo específico de biomarcadores na saliva para predizer e monitorar a obstrução ao fluxo aéreo em pacientes com DPOC...

The increased expression of matrix metalloproteinases (MMP) is considered a key factor in the development of chronic obstructive pulmonary disease (COPD). This study aimed at assessing expression levels of MMP-2 and MMP-9 in saliva from patients with COPD, comparing them to those of healthy subjects, thus assessing the feasibility of characterizing specific biomarkers for COPD. Patients with COPD (n=16) and healthy controls (n=9) were selected; both groups submitted to spirometry and to collection of saliva samples. Saliva levels of MMP-2 and MMP-9 were determined by Western blot. MMP-2 and MMP-9 levels were significantly higher in COPD patients than in control subjects. In COPD patients, a moderate, negative correlation was found between MMP-2 concentration and forced expiatory volume at the first second (r= -0.582; p=0.014). These findings open new perspectives to study specific biomarkers in saliva to predict and monitor airway obstruction in COPD patients...